Investment firm Fidelity Management & Research Company led a $100m Series C round in dMed, a full-service clinical contract research organization, with participation from Sequoia Capital, Kaiser Foundation Hospitals, E Fund, Qiming Venture Partners, Lilly Asia Ventures and Vivo Capital. "We are extremely gratified by continued strong support from an impressive group of international institutions. A key goal in the current round is to expand our investor base to include long-term public market-focused institutions and strategic partners in order to prepare for a future IPO. Fidelity, which led the Series C, is an excellent example of the expansion to the strong foundation we are building to continue the company's rapid organic growth and support our acquisition strategy," Lingshi Tan, dMed Founder, Chairman and CEO.